Dr. Mekan brings a combined 18 years of experience in hematology and oncology across academic research, clinical practice and biopharmaceutical industry development, and I am excited to welcome her to ...

Australia leads the world in community-based needle programs. Yet they’re not used in prisons – which are hotspots for ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating lenacapavir, a long-lasting HIV prevention and treatment drug.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

As part of its commitment to advance healthcare innovation, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the ...

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical app ...

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...

The most recent trading session ended with Gilead Sciences (GILD) standing at $104.90, reflecting a -0.74% shift from the previouse trading day's closing. This change was narrower than the S&P 500's ...